Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cediranib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
Indications Adenocarcinoma; Colorectal cancer; Leiomyosarcoma; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic
Acronyms DAPPER

12 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Jan 2025.
12 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2025.
11 Aug 2023 Results of partial response (PR) with increase in CD8 T-cells and macrophages in the TME during treatment and transcriptome analysis (n=30) published in the Clinical Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com